title: Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.
abstract: A multicentre phase II trial was undertaken to evaluate the activity and toxicity of docetaxel plus cisplatin as first-line chemotherapy in patients with urothelial cancer. Thirty-eight patients with locally advanced or metastatic transitional-cell carcinoma of the bladder, renal pelvis or ureter received the combination of docetaxel 75 mg m(-2) and cisplatin 75 mg m(-2) on day 1 and repeated every 21 days, to a maximum of six cycles. The median delivered dose-intensity was 98% (range 79-102%) of the planned dose for both drugs. There were seven complete responses and 15 partial responses, for and overall response rate of 58% (95% CI, 41-74%). Responses were even seen in three patients with hepatic metastases. The median time to progression was 6.9 months, and the median overall survival was 10.4 months. Two patients who achieved CR status remain free of disease at 4 and 3 years respectively. Grade 3-4 granulocytopenia occurred in 27 patients, resulting in five episodes of febrile neutropenia. There was one toxic death in a patient with grade 4 granulocytopenia who developed acute abdomen. Grade 3-4 thrombocytopenia was rare (one patient). Other grade 3-4 toxicities observed were anaemia (three patients), vomiting (five patients), diarrhoea (four patients), peripheral neuropathy (two patients) and non-neutropenic infections (seven patients). Docetaxel plus cisplatin is an effective and well-tolerated regimen for the treatment of advanced urothelial cancer, and warrants further investigation.
authors.affiliation: Institut Català d'Oncologia, Department of Medical Oncology, Avda Gran Vía km 2.7, 08907 L'Hospitalet, Barcelona, Spain. garciadelmuro@csub.scs.es
authors.forename: X
authors.initials: X
authors.lastname: Garcia del Muro
authors.forename: E
authors.initials: E
authors.lastname: Marcuello
authors.forename: J
authors.initials: J
authors.lastname: Gumá
authors.forename: L
authors.initials: L
authors.lastname: Paz-Ares
authors.forename: M A
authors.initials: MA
authors.lastname: Climent
authors.forename: J
authors.initials: J
authors.lastname: Carles
authors.forename: M Sánchez
authors.initials: MS
authors.lastname: Parra
authors.forename: J L
authors.initials: JL
authors.lastname: Tisaire
authors.forename: P
authors.initials: P
authors.lastname: Maroto
authors.forename: J R
authors.initials: JR
authors.lastname: Germá
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D043823:Taxoids; D013997:Time Factors; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019459:Urothelium
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel; D002945:Cisplatin